MedTrace Logo

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

NCT04215848 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-08-03

No results posted yet for this study

Summary

This study will evaluate the efficacy of as-needed Budesonide/formoterol Turbuhaler 160/4.5 µg/d in the period of step down in well controlled asthmatic patient comparing with standard maintenance therapy in step-2 management in asthma guildeline which is low dose inhaled corticosteroid.

Conditions

Interventions

DRUG

Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder

After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.

DRUG

Budesonide 200Mcg Inhalation Powder

After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily

Sponsors & Collaborators

  • Hat Yai Medical Education Center

    lead OTHER

Principal Investigators

  • Narongwit Nakwan, M.D. · HatYai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-10-10
Completion
2022-05-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04215848 on ClinicalTrials.gov